SAN DIEGO, June 15, 2026 /PRNewswire/ — Hillhurst Biopharmaceuticals Inc. (“Hillhurst Bio”), a clinical-stage biopharmaceutical company focused on developing novel oral liquid drug products based on known inhaled therapeutics, today announced that the first subject has been dosed in its…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
